Poseida Therapeutics, Inc.

54 articles with Poseida Therapeutics, Inc.

• Poseida Therapeutics Appoints Cynthia Collins to Board of Directors

  7/26/2021

  Poseida Therapeutics, Inc. today announced the appointment of biotechnology industry veteran Cynthia Collins to its Board of Directors, effective July 23, 2021.

• Cellares and Poseida Therapeutics Partner to Accelerate Cell Therapy Manufacturing

  7/14/2021

  Cellares Corporation, a life sciences technology company pioneering a revolutionary automated approach to cell therapy manufacturing, announced that Poseida Therapeutics, Inc., a clinical-stage biopharmaceutical company utilizing proprietary genetic engineering platform technologies to create cell and gene therapeutics with the capacity to cure, has joined its Early Access Partnership Program.

• Poseida Therapeutics Announces Virtual 2021 Annual Meeting of Stockholders

  6/2/2021

  Poseida Therapeutics, Inc., a clinical-stage biopharmaceutical company utilizing proprietary genetic engineering platform technologies to create cell and gene therapeutics with the capacity to cure, announced that its Annual Meeting of Stockholders will be held virtually via live webcast on Wednesday, June 16, 2021 at 1:00pm PT.

• Poseida Therapeutics Reports Program Updates and Financial Results for the First Quarter 2021

  5/11/2021

  Poseida Therapeutics, Inc., a clinical-stage biopharmaceutical company utilizing proprietary genetic engineering platform technologies to create cell and gene therapeutics with the capacity to cure, announced program updates and financial results for the first quarter ended March 31, 2021.

• Poseida Therapeutics Presents Encouraging Preclinical Data Across its CAR-T and Gene Therapy Programs at the American Society of Gene and Cell Therapy 2021 Virtual Annual Meeting

  5/11/2021

  Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage biopharmaceutical company utilizing proprietary genetic engineering platform technologies to create cell and gene therapeutics with the capacity to cure,  today will give multiple oral and poster presentations at the American Society of Gene and Cell Therapy 2021 Virtual Annual Meeting

• 

  Cutting-Edge Tech: Highlights from the American Society of Gene & Cell Therapy

  5/11/2021

  The 24th Annual meeting of the American Society of Gene & Cell Therapy presents cutting-edge work in the booming area of gene and cell therapy. Here’s a look at a few of the highlights.

• Poseida Therapeutics Announces Key Additions to Immuno-Oncology Scientific Advisory Board

  5/6/2021

  Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage biopharmaceutical company utilizing proprietary genetic engineering platform technologies to create cell and gene therapeutics with the capacity to cure, today announced the appointment of three new members to its Scientific Advisory Board (SAB)

• Poseida Therapeutics to Present at BofA Securities 2021 Virtual Health Care Conference

  5/5/2021

    Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage biopharmaceutical company utilizing proprietary genetic engineering platform technologies to create cell and gene therapeutics with the capacity to cure, today announced that the Company's CEO, Eric Ostertag , MD, PhD, will present at the BofA Securities 2021 Virtual Health Care Conference

• Poseida Therapeutics to Present at American Society of Gene and Cell Therapy 2021 Annual Meeting

  4/27/2021

  Poseida Therapeutics, Inc. (NASDAQ: PSTX), a clinical-stage biopharmaceutical company utilizing proprietary genetic engineering platform technologies to create cell and gene therapeutics with the capacity to cure, today announced three data presentations to be delivered at the upcoming American Society of Gene and Cell Therapy (ASGCT) 24th Annual Meeting, being held virtually May 11-14, 2021.

• Poseida Therapeutics to Present at Upcoming Virtual Investor Conferences

  4/8/2021

  Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage biopharmaceutical company utilizing proprietary genetic engineering platform technologies to create cell and gene therapeutics with the capacity to cure, today announced that the Company will participate in the following upcoming virtual investor conferences:

• Poseida Therapeutics Announces Carl June, M.D., to Chair Immuno-Oncology Scientific Advisory Board

  3/23/2021

   Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage biopharmaceutical company utilizing proprietary genetic engineering platform technologies to create cell and gene therapeutics with the capacity to cure, today announced the appointment of distinguished scientist Carl June, M.D., who will serve on Poseida's Scientific Advisory Board (SAB).

• Poseida Therapeutics Reports Program Updates and Financial Results for the Fourth Quarter and Full Year 2020

  3/11/2021

  Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage biopharmaceutical company utilizing proprietary genetic engineering platform technologies to create cell and gene therapeutics with the capacity to cure, today announced program updates and financial results for the fourth quarter and full year ended December 31, 2020.

• Poseida Therapeutics Provides Update on Key Programs and Developments During R&D Day

  2/24/2021

  Poseida Therapeutics, Inc. (NASDAQ: PSTX), a clinical-stage biopharmaceutical company utilizing proprietary genetic engineering platform technologies to create cell and gene therapeutics with the capacity to cure, today announced that the Company plans to highlight its clinical and preclinical pipeline progress during a virtual R&D Day

• Poseida Therapeutics to Host Virtual R&D Day on February 24, 2021

  2/10/2021

  Poseida Therapeutics, Inc. (NASDAQ: PSTX), a clinical-stage biopharmaceutical company utilizing proprietary gene engineering platform technologies to create cell and gene therapeutics with the capacity to cure, today announced that it will host a virtual R&D Day at 10:00 am - 2:00 pm ET / 7:00 - 11:00 am PT on Wednesday, February 24, 2021.

• Poseida Therapeutics to Participate in Guggenheim Healthcare Talks 2021 Oncology Day

  2/4/2021

  Poseida Therapeutics, Inc. (NASDAQ:PSTX), a clinical-stage biopharmaceutical company utilizing proprietary gene engineering platform technologies to create cell and gene therapeutics with the capacity to cure, today announced that Eric Ostertag , M.D., Ph.D., Poseida Therapeutics' Chief Executive Officer, will participate in a fireside chat on February 12, 2021

• Poseida Therapeutics to Participate in SternIR Virtual Corporate Access Event

  1/4/2021

  Poseida Therapeutics, Inc. (NASDAQ: PSTX), a clinical-stage biopharmaceutical company utilizing proprietary gene engineering platform technologies to create cell and gene therapeutics with the capacity to cure, today announced that Eric Ostertag , M.D., Ph.D., Poseida Therapeutics' Chief Executive Officer, will participate in a pre-reco

• Poseida Therapeutics Added to NASDAQ Biotechnology Index

  12/18/2020

  Poseida Therapeutics, Inc. (NASDAQ: PSTX), a clinical-stage biopharmaceutical company utilizing proprietary gene engineering platform technologies to create cell and gene therapeutics with the capacity to cure, today announced that it has been selected for addition to the NASDAQ Biotechnology Index® (Nasdaq: NBI)

• Poseida Therapeutics Appoints Luke Corning to Board of Directors

  12/17/2020

  Poseida Therapeutics, Inc. (NASDAQ: PSTX), a clinical-stage biopharmaceutical company utilizing proprietary gene engineering platform technologies to create cell and gene therapeutics with the capacity to cure, today announced the appointment of Luke Corning, Portfolio Manager and Head of Credit at Pentwater Capital Management, to its Board of Directors. 

• 

  ASH 2020: CRISPR and Vertex's Potential Cure for Sickle Cell Disease and More Glimmers of Hope

  12/7/2020

  The American Society of Hematology (ASH) Annual Meeting & Exposition began December 5, and there were numerous presentations, abstracts and posters. Here’s a look at some of the stories out of the first day.

• Poseida Therapeutics Provides Update on Phase 1 Trial of P-BCMA-101 at the 2020 American Society of Hematology Annual Meeting

  12/5/2020

  Data from ongoing Phase 1 expansion trial using nanoplasmid demonstrated an improvement in efficacy over standard plasmid and a potentially best-in-class safety profile